Proteomics Secures US Patent for Endometriosis Blood Test

Proteomics International Laboratories has won a U.S. patent for its endometriosis test, allowing the company to advance its rollout plans ^[1].

The development is significant because it provides a non-invasive path to diagnosing a condition that often requires surgery for confirmation. By securing intellectual property in the U.S., the company can enter the world's biggest healthcare market ^[1].

The diagnostic product, known as PromarkerEndo, is a blood test designed to identify the presence of endometriosis ^[3]. The company is pursuing a global strategy to protect its technology, which includes securing a patent from the Japan Patent Office ^[3].

According to a report from Yahoo Finance, the Japanese patent ensures intellectual property protection for the diagnostic blood test ^[3]. This dual protection in the U.S. and Japan creates a foundation for the company to scale its diagnostic reach across different regulatory environments.

MSN said the U.S. patent advances plans to roll out the diagnostic product in the world’s biggest healthcare market ^[2]. The move reduces the risk for investors and partners by ensuring the company maintains exclusive rights to the PromarkerEndo technology while it navigates the commercialization process.

Proteomics International Laboratories has focused on the development of this blood-based approach to reduce the diagnostic delay associated with endometriosis. The company intends to use these patents to solidify its market position as it seeks to provide a faster, more accessible alternative to traditional diagnostic methods [1, 3].